AKTX - Akari Therapeutics

-

$undefined

N/A

(N/A)

Akari Therapeutics NasdaqCM:AKTX Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) and a novel discovery engine. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. In addition, its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. Further, the company develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.

Location: 22 Boston Wharf Road, Boston, MA, 02210, United States | Website: https://www.akaritx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

73.69B

Cash

2.582M

Avg Qtr Burn

-2.665M

Short % of Float

-

Insider Ownership

34.40%

Institutional Own.

0.98%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Nomacopan Details
Paroxysmal nocturnal hemoglobinuria

Phase 3

Update

Nomacopan Details
Hematopoietic stem cell transplantation thrombotic microangiopathies

Phase 3

Initiation

Phase 2

Update

Nomacopan Details
Atopic Keratoconjunctivitis

Phase 1/2

Update

Nomacopan Details
Geographic atrophy, Eye disease

Phase 1

Initiation

Nomacopan Details
Bullous pemphigoid

Failed

Discontinued